Strides Injectables Re-Entry Shifts Into High Gear

Corporate Reset Delivers A Strong Second Quarter

Strides Pharma Science, which has reported a strong second-quarter performance, said its reborn injectables business will “be full-blown” in several markets by December thanks to the expiry of a non-compete agreement with Mylan.

Gearstick
Strides’ injectables plans are shifting into a higher gear • Source: Shutterstock

Strides Pharma Science’s reborn injectables business will be going strong in several markets by the end of 2019, founder and managing director Arun Kumar has told analysts, adding that the company’s robust second-quarter earnings performance – in which earnings before interest, tax, depreciation and amortization rocketed 210% year-on-year – has shown that being a corporate “contrarian” pays off.

Kumar said Strides, which focuses on tough-to-make niche products sold in over 100 countries, was very “excited about rebuilding this...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Strategy

More from Business